Half of patients with heart failure have Heart Failure with Preserved Ejection Fraction (HFpEF).  Join host, Geoff Wall, as he talks about the new guidelines from the American College of Cardiology for diagnosis, treatment, and challenges in therapy for persons with HFpEF.

The GameChanger
HFpEF is the fastest growing cause of heart failure and is often difficult to diagnose. New therapies are shown to improve symptoms and decrease hospitalizations. Management of comorbid conditions, like obesity and diabetes, is critical to optimizing care.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Reference
Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19. PMID: 37137593.
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)

CE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the H2FPEF scoring system for HFpEF diagnosis
2. Apply the new practice guidelines to HFpEF patient pharmacotherapy
 
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-228-H01-P
Initial release date: 6/19/2023
Expiration date: 6/19/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram